Mengchuan Wang

Mengchuan Wang

Auto-generated profile, based on publicly available information

Mengchuan Wang

Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MWM. Wang
M. Wang
SJS. Ji
S. Ji
GSG. Shao
G. Shao
JZJ. Zhang
J. Zhang
KZK. Zhao
K. Zhao
AWAiguo Wu
Aiguo Wu

28 May 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
SLShan shan Lei
Shan shan Lei
PFPeizhi Fan
Peizhi Fan
MWMengchuan Wang
Mengchuan Wang
CZChaojie Zhang
Chaojie Zhang
YJYu Jiang
Yu Jiang
AWAiguo Wu
Aiguo Wu
Based on its pathological characteristics, breast cancer is a highly heterogeneous disease. Triple negative breast cancer (TNBC) is an aggressive subtype, and due to a lack of effective therapeutic targets, patients with TNBC do not significantly benefit from endocrine or anti‑HER2 therapy. Conventional chemotherapy has been regarded as the only systemic therapy option for TNBC, but its therapeutic efficacy remains limited. Estrogen receptor β (ERβ) has been identified as a tumor suppressor in TNBC. Therefore, the aim of the present study was to identify the role of ERβ in regulating the response to chemotherapy, and to investigate its underlying mechanism in TNBC. MDA‑MB‑231 and BT549 cells were treated with doxorubicin (DOX), liquiritigenin [Liq, (Chengdu Biopurify Phytochemicals, Ltd.); a specific ERβ agonist], or a combination of DOX and Liq in vitro. The effects of various treatments on cell viability and proliferation were measured using the Cell Counting Kit‑8 and colony‑formation assays, respectively. MDA‑MB‑231 and ERβ knockdown (ERβ‑KD) MDA‑MB‑231 cells were selected for the establishment of ERα‑/ERβ+ and ERα‑/ERβ‑ cell models, respectively. The two cell models were treated with DOX, Liq or a combination of DOX and Liq. The effects of the treatment on the PI3K/AKT/mTOR signaling pathway were evaluated by assessing the protein expression levels of AKT and mTOR using western blot analysis. Low Liq concentrations increased the sensitivity of MDA‑MB‑231 and BT549 cells to DOX. Moreover, the synergistic effect of Liq and DOX treatment was associated with the inhibition of the PI3K/AKT/mTOR signaling pathway in MDA‑MB‑231 cells, and the effect was ERβ‑dependent. The results suggested that elevated ERβ expression was associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway; therefore, the combined use of conventional chemotherapeutic drugs with ERβ agonists may serve as an effective therapy for TNBC.

1 October 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
KZKankan Zhao
Kankan Zhao
MWMengchuan Wang
Mengchuan Wang
AWAiguo Wu
Aiguo Wu
Background: Adenosine triphosphatase H+ transporting accessory protein 2 (ATP6AP2), also known as (pro)renin receptor, is implicated in tumorigenesis and the progression of several types of cancer. This study investigated the role of ATP6AP2 in breast cancer. Methods: UALCAN and ONCOMINE datasets were utilized to compare transcript levels of ATP6AP2 in breast cancer and normal tissues. GOBO datasets were applied to examine ATP6AP2 expression in different breast cancer cell lines. We used the cBioPortal website to explore the gene alterations and copy number alterations of ATP6AP2 in breast cancer. Cell Counting Kit-8 and transwell assays were conducted to evaluate ATP6AP2 function in MCF-7 breast cancer cells. Finally, we used the cBioPortal website to establish the interaction network of ATP6AP2 in breast cancer and performed functional enrichment analysis based on Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways. Results: ATP6AP2 was overexpressed in breast cancer tissues and breast cancer cell lines in the UALCAN, ONCOMINE, and GOBO datasets. The major type of ATP6AP2 alteration was mRNA upregulation. Moreover, ATP6AP2 was most highly expressed in luminal type breast cancer. Finally, ATP6AP2 knockdown reduced MCF-7 cell proliferation, invasion and migration. Functional enrichment analysis suggested that ATP6AP2 regulates several cancer-related pathways, especially the Wnt/β-catenin signaling pathway. Conclusion: Applying multi-dimensional analytical methods, we demonstrate that ATP6AP2 is upregulated in breast cancer and may promote its development and progression.

4 December 2025 in SLAS Technology
Verified
Journal Article
Open access
ZPZhengqi Peng
Zhengqi Peng
QCQian Chen
Qian Chen
PNPengkhun Nov
Pengkhun Nov
MSMohsin Farid Sulehri
Mohsin Farid Sulehri
YLYujing Liu
Yujing Liu
MWMengchuan Wang
Mengchuan Wang
Cold tumors, characterized by low cytotoxic T cell infiltration, limit immunotherapy efficacy. Current strategies often depend on tumor-specific antigens or non-specific immune activation, restricting translational potential. Here, we present a peptide-based platform that leverages intratumoral expression of influenza-derived peptides to redirect virus-specific CD8⁺ T cells and remodel the tumor immune microenvironment in an antigen-independent manner. In murine 4T1 and CT26 tumor models, the immunodominant influenza A virus peptide NP147-155 was delivered via intratumoral peptide injection or stable lentiviral expression. Immune remodeling was assessed using flow cytometry, cytokine profiling, and transcriptomic profiling. Differential gene expression and pathway analyses identified mechanisms underlying cold-to-hot TME conversion. Intratumoral NP147-155 expression robustly activated virus-specific CD8⁺ T cells and enhanced IFN-γ secretion. Transcriptomic profiling revealed upregulation of genes associated with cytotoxicity, chemokine signaling, antigen presentation, and the NKG2D-NKG2DL pathway, consistent with increased T cell infiltration and conversion of cold tumors into hot tumors. Tumor growth was significantly suppressed, and durable anti-tumor immunity was established, including in MHC class I-deficient tumors. This study demonstrates a peptide-based platform to remodel cold tumor immune microenvironments. Integration of transcriptomic profiling provides mechanistic insights and establishes a robust workflow for evaluating immunomodulatory technologies. This tumor-agnostic approach may enhance anti-tumor immunity and improve immunotherapy efficacy in cold tumors.